PURPOSE: To determine the efficacy and @entity137 of UFT-E plus oral @entity4181 in the treatment of @entity1 with advanced @entity14 . MATERIALS AND METHODS: Forty-three @entity1 with advanced, bidimensionally measurable @entity14 were enrolled in the trial. No @entity1 had received prior palliative chemotherapy. The @entity1 that had received previous adjuvant chemotherapy were enrolled when more than 6 months had elapsed after the completion of adjuvant therapy. @entity1 were treated with 300 mg/m2/day of UFT-E (tegafur-based) plus 90 mg/day of @entity4181 administered orally in three divided daily doses, every 8 hours for 28 days followed by a 7-day rest period. Response was evaluated after two or three courses of therapy. RESULTS: Thirty-six of forty-three @entity1 were evaluable for response; seven dropped out due to infection, @entity137 and @entity1 ' refusal. Ten @entity1 had partial responses and one @entity1 complete response (response rate, 31%; 95% confidence interval, 16~46%). The median response duration for the UFT-E plus @entity4181 regimen was 28 weeks. Grade III @entity137 was seen in one case, with @entity294 . CONCLUSION: This oral regimen proved effective and well tolerated. This schema also avoided inconveniences, such as hospitalization and the use of infusion pumps, which are associated with @entity1487 infusion regimens. The regimen used showed minimal @entity137 , especially in the upper digestive tract, with good @entity1 compliance.

A Phase II Trial of UFT-E and Oral XXXX in Advanced @entity14 .

@entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin', 'calcium leucovorin'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal adenocarcinoma', 'colorectal cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU']
@entity4181 :: (MESH:D002955,Chemical) :: ['Leucovorin']
